Erastapex Co 5mg/20mg 30 tablets

Tradename

Erastapex Co

Erastapex Co.

Compound:

Each tablet contains:

Olmesartan medoxomil 20 mg

Amlodipine 5 mg

Auxiliary components:

pregelatinized starch, silicified microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Properties

Combined antihypertensive drug, which includes an angiotensin II receptor antagonist — olmesartan medoxomil and a blocker of slow calcium channels — amlodipine. The combination of two active ingredients has a synergistic antihypertensive effect, as a result of which blood pressure decreases to a greater extent than when each of them is taken separately.

Indications

Essential hypertension (with the ineffectiveness of monotherapy with olmesartan medoxomil or amlodipine).

Dosage and administration

The drug is taken orally, 1 time / day, at the same time, regardless of the meal time, without chewing, drinking a sufficient amount of liquid (for example, a glass of water).

Before prescribing a combination drug, it is recommended to preselect the doses of each of the active substances separately (olmesartan medoxomil and amlodipine).

The recommended dose is 1 tab. a preparation containing 5 mg of amlodipine and 20 mg of olmesartan medoxomil.

Contraindications

Severe liver failure (more than 9 points on the Child-Pugh scale); obstruction of the biliary tract and cholestasis; severe renal failure (CC less than 20 ml / min, there is no clinical experience); condition after kidney transplantation (no clinical experience); conditions accompanied by a pronounced violation of the outflow of blood from the left ventricle (for example, severe aortic stenosis); severe arterial hypotension (SBP less than 90 mm Hg); shock (including cardiogenic); hemodynamically unstable heart failure after myocardial infarction; simultaneous use with aliskiren and aliskiren-containing drugs in patients with diabetes mellitus and / or impaired renal function (GFR less than 60 ml / min / 1.732 m2 of body surface area); pregnancy; breastfeeding period; age up to 18 years (efficacy and safety have not been established); hypersensitivity to olmesartan medoxomil, amlodipine and other dihydropyridine derivatives or to other components of the drug.

With caution: stenosis of the aortic and mitral valve; hypertrophic obstructive cardiomyopathy; simultaneous use with lithium preparations; hyperkalemia, hyponatremia; hypovolemia (including due to diarrhea, vomiting or the simultaneous use of diuretics), as well as in patients on a diet with limited salt intake; renal failure of mild and moderate severity (CC 20-60 ml / min); primary aldosteronism; renovascular hypertension (bilateral stenosis of the renal arteries or stenosis of the artery of a single kidney); other conditions accompanied by activation of the RAAS; chronic heart failure (FC III-IV according to the NYHA classification); chronic forms of ischemic heart disease; acute forms of coronary artery disease (acute myocardial infarction, including within one month after it; unstable angina pectoris); SSSU; arterial hypotension; cerebrovascular diseases; liver failure of mild to moderate severity (less than 9 points on the Child-Pugh scale); age over 65; use in patients of the black race.

Precautionary measures:

Side effects

From the immune system: rarely — allergic reactions, hypersensitivity reactions, urticaria.

From the nervous system: often — dizziness, headache; infrequently — hypesthesia, paresthesia, postural dizziness, drowsiness; rarely — syncope.

Mental disorders: infrequently — decreased libido.